Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
MAP Kinase Kinase 1
MAP Kinase Kinase 2
Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease. (Funded by the American Thyroid Association and others; ClinicalTrials.gov number, NCT00970359.).